These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 23824129)

  • 1. Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy.
    Habermehl D; Henkner K; Ecker S; Jäkel O; Debus J; Combs SE
    J Radiat Res; 2013 Jul; 54 Suppl 1(Suppl 1):i61-8. PubMed ID: 23824129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of optimal fiducial marker across image-guided radiation therapy (IGRT) modalities: visibility and artifact analysis of gold, carbon, and polymer fiducial markers.
    Handsfield LL; Yue NJ; Zhou J; Chen T; Goyal S
    J Appl Clin Med Phys; 2012 Sep; 13(5):3976. PubMed ID: 22955665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative evaluation of fiducial markers for radiotherapy imaging.
    Chan MF; Cohen GN; Deasy JO
    Technol Cancer Res Treat; 2015 Jun; 14(3):298-304. PubMed ID: 25230715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer.
    De Roover R; Crijns W; Poels K; Peeters R; Draulans C; Haustermans K; Depuydt T
    Med Phys; 2018 May; 45(5):2205-2217. PubMed ID: 29537613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of inter- and intrafractional motion of liver tumors using interstitial markers and implantable electromagnetic radiotransmitters in the context of image-guided radiotherapy (IGRT) - the ESMERALDA trial.
    Habermehl D; Naumann P; Bendl R; Oelfke U; Nill S; Debus J; Combs SE
    Radiat Oncol; 2015 Jul; 10():143. PubMed ID: 26169281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Particle therapy of moving targets-the strategies for tumour motion monitoring and moving targets irradiation.
    Kubiak T
    Br J Radiol; 2016 Oct; 89(1066):20150275. PubMed ID: 27376637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential failure risk of the cone-beam computed tomography-based planning target volume margin definition for prostate image-guided radiotherapy based on a prospective single-institutional hybrid analysis.
    Hirose K; Sato M; Hatayama Y; Kawaguchi H; Komai F; Sohma M; Obara H; Suzuki M; Tanaka M; Fujioka I; Ichise K; Takai Y; Aoki M
    Radiat Oncol; 2018 Jun; 13(1):106. PubMed ID: 29880006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging.
    Osman SOS; Russell E; King RB; Crowther K; Jain S; McGrath C; Hounsell AR; Prise KM; McGarry CK
    Radiat Oncol; 2019 Dec; 14(1):237. PubMed ID: 31878967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy.
    Scherman Rydhög J; Irming Jølck R; Andresen TL; Munck Af Rosenschöld P
    Med Phys; 2015 Jun; 42(6):2818-26. PubMed ID: 26127034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fiducial markers implanted during prostate brachytherapy for guiding conformal external beam radiation therapy.
    Welsh JS; Berta C; Borzillary S; Sam C; Shickell D; Nobile L; Greenberg M; Weiss S; Detorie N
    Technol Cancer Res Treat; 2004 Aug; 3(4):359-64. PubMed ID: 15270586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visibility and artifacts of gold fiducial markers used for image guided radiation therapy of pancreatic cancer on MRI.
    Gurney-Champion OJ; Lens E; van der Horst A; Houweling AC; Klaassen R; van Hooft JE; Stoker J; van Tienhoven G; Nederveen AJ; Bel A
    Med Phys; 2015 May; 42(5):2638-47. PubMed ID: 25979055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel artifact-robust and highly visible zinc solid fiducial marker for kilovoltage x-ray image-guided radiation therapy.
    Wang T; Inubushi S; Ikeo N; Mukai T; Okumura K; Akasaka H; Yada R; Yoshida K; Miyawaki D; Ishihara T; Nakaoka A; Sasaki R
    Med Phys; 2020 Oct; 47(10):4703-4710. PubMed ID: 32696571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing the TrueBeam Advanced Imaging Package to monitor intrafraction motion with periodic kV imaging and automatic marker detection during VMAT prostate treatments.
    Korpics MC; Rokni M; Degnan M; Aydogan B; Liauw SL; Redler G
    J Appl Clin Med Phys; 2020 Mar; 21(3):184-191. PubMed ID: 31981305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visibility of fiducial markers used for image-guided radiation therapy on optical coherence tomography for registration with CT: An esophageal phantom study.
    Jelvehgaran P; Alderliesten T; Weda JJA; de Bruin M; Faber DJ; Hulshof MCCM; van Leeuwen TG; van Herk M; de Boer JF
    Med Phys; 2017 Dec; 44(12):6570-6582. PubMed ID: 29023771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical investigation for developing injectable fiducial markers using a mixture of BaSO4 and biodegradable polymer for proton therapy.
    Ahn SH; Gil MS; Lee DS; Han Y; Park HC; Sohn JW; Kim HY; Shin EH; Yu JI; Noh JM; Cho JS; Ahn SH; Choi DH
    Med Phys; 2015 May; 42(5):2626-37. PubMed ID: 25979054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anthropomorphic multimodality (CT/MRI) head phantom prototype for end-to-end tests in ion radiotherapy.
    Gallas RR; Hünemohr N; Runz A; Niebuhr NI; Jäkel O; Greilich S
    Z Med Phys; 2015 Dec; 25(4):391-399. PubMed ID: 26189015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of MRI visibility and artifacts at 3T of liquid fiducial marker in a pancreas tissue-mimicking phantom.
    Schneider S; Jølck RI; Troost EGC; Hoffmann AL
    Med Phys; 2018 Jan; 45(1):37-47. PubMed ID: 29136287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplitude-based gated phase-controlled rescanning in carbon-ion scanning beam treatment planning under irregular breathing conditions using lung and liver 4DCTs.
    Mori S; Inaniwa T; Furukawa T; Takahashi W; Nakajima M; Shirai T; Noda K; Yasuda S; Yamamoto N
    J Radiat Res; 2014 Sep; 55(5):948-58. PubMed ID: 24835238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate.
    Huang JY; Newhauser WD; Zhu XR; Lee AK; Kudchadker RJ
    Phys Med Biol; 2011 Aug; 56(16):5287-302. PubMed ID: 21799236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma.
    Apolle R; Brückner S; Frosch S; Rehm M; Thiele J; Valentini C; Lohaus F; Babatz J; Aust DE; Hampe J; Troost EGC
    Radiother Oncol; 2019 Apr; 133():28-34. PubMed ID: 30935578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.